IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic Cancer
Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of the trial is to identify the dose of gemcitabine given as a 2-hour
intravenous (iv) infusion that can be administered in combination with ZD1839 250 mg once
daily and a standard course (45 Grays [Gy]) of radiotherapy in patients with locally
advanced, unresectable pancreatic cancer.